Introduction Although all cells within the body are exposed to steroid hormones, their physiological actions are limited to those tissues which contain intracellular binding proteins, termed receptors. These proteins specifically bind the individual classes of steroid hormones with high affinity and transmit the steroid signal to sensitive genes located throughout the chromatin. The type of response subsequently induced is dependent on both the developmental stage and differentiation status of the target tissue, but may involve the control of such diverse end points as cell proliferation, cell death, secretory activity, and cellular mobility. Importantly, the ability of steroid hormones to influence these characteristics is retained in many disease states, notably in certain cancers originating in steroid hormone sensitive tissues including carcinomas of the breast,' genital tract,23 gastrointestinaI tract,4 pancreas,5 lung,6 and also intracranial tumours.7 This has been harnessed therapeutically, with drugs which modify the cellular levels or actions of steroid hormones being commonly used in the treatment of breast, endometrial and prostate cancer.89 These tumours frequently retain steroid hormone receptors and their measurement is currently used diagnostically in several centres to identify potential endocrine responsiveness.
As steroid sensitive cancers are relatively common and as cellular transitions associated with the loss of their hormone sensitivity invariably worsen the prognosis for a patient, considerable effort has been afforded to their study. The examination of steroid hormone receptors is pivotal to our understanding of endocrine sensitivity and therefore the current article attempts to summarise our present knowledge ofthese proteins specifically in those areas of cancer biology which we hope are of particular interest to the pathologist. . This is exemplified by the oestrogen regulated gene pS2 (pNR2) which has been shown to be sensitive to the growth factors transforming growth factor cz (TGFoc), epidermal growth factor and also insulin-like growth factor I.27 A further example is seen with PR, traditionally an oestrogen regulated protein, which can also be activated through dopaminergic and adrenergic signalling mechanisms.28 Such interactions raise interesting questions concerning the role of cross-talk between steroid hormone receptors and other signalling pathways in the regulation of transcriptional efficiency, constitutive action of the receptor and acquisition of endocrine resistance. A knowledge of such pathways may provide previously unrecognised opportunities for tumour therapy.'°M ethods of detection The observation that hormone sensitive tissues were able to take up and retain radiolabelled steroids against a concentration gradient of the steroid26 lead to the initial discovery of steroid hormone receptors. This property was subsequently exploited in "test tube" biochemical assays, notably dextran coated charcoal (DCC) adsorption ligand binding assays (LBA' 26), generating information on the concentration of steroid hormone receptors within solubilised tissue extracts, together with their binding affinity constants. Unfortunately, the ease of performing these assays and also their subsequent clinical value varies between tumour types and surgical procedures used. Thus, while breast and endometrial cancer samples are relatively accessible enabling valuable data to be readily obtained, it is often essential to remove prostate tumour specimens by transurethral sectioning, a procedure which generates elevated temperatures and consequently is potentially damaging to any receptor proteins. 26 Furthermore, the assays are also influenced by both the cellularity of the cancer and the content and associated steroid hormone receptor status of normal or benign tissue. These factors may contribute towards falsely negative or positive receptor results.
More recently developed methodologies rely on direct antigen recognition rather than steroid binding activity, utilising monoclonal antibodies29 specific for the various steroid receptors in both enzyme immunoassays (for example, oestrogen receptor enzyme immunoassay (ER-EIA)"0) and also immunocytochemistry (for example, oestrogen receptor immunocytochemical assay (ER-ICA) 26 31 Early immunocytochemical studies using antibodies directed against ER (for example, H222 antibody, available in the ER-ICA kit" from Abbott Diagnostics, North Chicago, Illinois, USA) showed that the protein is localised exclusively within the epithelial cell nuclei in suitably fixed cryosections" (that is, frozen specimens stored at -700C, sectioned and fixed for 10 to 15 minutes in 3-7% formaldehyde/phosphate buffered saline at room temperature; post-fixed in methanol (five minutes) and acetone (three minutes) at -200C) of normal and cancerous genital tract, breast, pituitary, and liver. This observation was at odds with the previously held view of this receptor as a cytosolic protein which was subsequently translocated to the nucleus following its activation by oestrogens. It is now believed that, with the exception of glucocorticoid receptors, each class of steroid hormone receptor resides predominantly in the nuclei of steroid sensitive cells.'
Using such antibodies, ER (H222 and 1D5 (Dako, High Wycombe, UK)) and PR may now also be reliably localised in 10% buffered formalin fixed (exposed to formalin for no longer than 24 hours as prolonged fixation results both in decreased receptor immunoreactivity and in the appearance of non-specific cytoplasmic staining), paraffin wax embedded material following the re-exposure of masked antigenic determinants by controlled protease digestion of the tissue sections'6 or microwave treatment. ' In adjuvant endocrine trials greatest benefit is predictably observed in those women with ER/ PR rich cancers. '26 51 In the UK the use of these assays to tailor therapy to the tumour characteristics of individual patients is only sparingly applied and a more pragmatic approach is frequently undertaken which uses the relatively non-toxic antioestrogenic drug tamoxifen to assess endocrine responsiveness clinically.42 This approach has arisen primarily from inaccuracies observed in the prediction of clinical response by steroid receptor assessment.52 An immunohistochemical approach to steroid hormone receptor measurements, however, facilitates the construction of a broader biological view of the tumour and demonstrates that further elements other than steroid receptors can influence and correlate closely with clinical response to endocrine treatments. Thus, the increased expression of various peptide growth factors (notably TGFc (53) and their receptors (EGFR5455), proto-oncogene products (c-erbB254) and also markers indicative of cell proliferative activity (Ki6754) have been associated with loss of endocrine sensitivity40 despite positivity for steroid receptors often being maintained.
It is also possible that further anomalies could arise in the prediction of clinical response to endocrine therapy using steroid receptor profiles if these receptors were occasionally nonfunctional. An interesting approach to the identification of functionality of steroid receptors has been to measure their gene products. It is fair to say, however, that the identification of target genes involved in the hormonal control of cell behaviour has lagged behind the analysis of the structure and function of these receptors as transcription factors. Most progress has been made with oestrogen regulated genes, with several groups reporting successful cloning strategies. PR52, pS256, pLIV1,57 and cathepsin D58 have been described as oestrogen regulated proteins, with all but cathepsin D showing enrichment within ER positive disease.565759
Where studied, the expression of oestrogen regulated gene products in clinical breast cancer, although often associated with endocrine responsiveness and invariably also having prognostic value,56 does not add substantially to the information that may be gained from ER measurements alone. Where the expression of several oestrogen regulated genes has been studied within the breast cancer population, it is evident that they are not always co-expressed in ER positive disease. Their differential expression may reflect differing biological behaviour patterns of the tumours, with-for example, ER/pLIVl dual positivity significantly correlating with lymph node involvement in contrast to ER/pS2 positivity. 60 Potentially, the control of such activities may reside in variations in the promoters of individual genes or in the sensitivity of the promoters to mutations in the ER. Possibly the most important value of polymerase chain reaction (PCR) amplification technology in steroid receptor determination is the highly sensitive detection of rare defects in the steroid receptor genes and their mRNAs.61 An expanding number of ER mutations have now been documented, including those which can lead to either a loss of either the hormone or DNA binding domain. Several mutations have been successfully identified, albeit at a low frequency, in human breast cancers in vivo.6263
These frequently occur through frame shift/ termination mutations in the ER gene, generating what has been appropriately described by the group from Texas as "outlaw receptors".62 The functional significance of these mutants has been demonstrated by Fuqua et a164 who showed that ER lacking exon 5, encoding the hormone binding domain, constitutively activated transcription of a normally oestrogen dependent gene construct in yeast cells. These observations show that a mutant ER could potentially dramatically affect oestrogen responsiveness of a cancer by acting as a constitutive activator of gene expression even in the absence of oestrogens,62 and thus such mutations could potentially be of some importance in controlling breast cancer growth observed following the acquisition of hormone/ antihormone resistance. 63 Similarly, mutations in the DNA binding domain could alter the DNA specificity of the receptor leading to promiscuous activation of genes not normally responsive to oestrogens, or result in the loss of DNA binding. Most 
